Evidence map›Paper›PMID 32767466›Full record

ArticleDermatologic therapy2020

Changing trends in dermatology practice during COVID-19 pandemic: A single tertiary center experience.

Efsun Tanacan, Gulhan Aksoy Sarac, Mehmet Ali Can Emeksiz, Didem Dincer Rota, Fatma Gulru Erdogan

Abstract read
In one paragraph

Article in Dermatologic therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Efsun TanacanDepartment of Dermatology and Venereology, Ufuk University Hospital, Ankara, Turkey.ORCID https://orcid.org/0000-0003-1975-7460
Gulhan Aksoy SaracDepartment of Dermatology and Venereology, Ufuk University Hospital, Ankara, Turkey.ORCID https://orcid.org/0000-0002-8480-4561
Mehmet Ali Can EmeksizDepartment of Dermatology and Venereology, Ufuk University Hospital, Ankara, Turkey.ORCID https://orcid.org/0000-0002-0933-4619
Didem Dincer RotaDepartment of Dermatology and Venereology, Ufuk University Hospital, Ankara, Turkey.
Fatma Gulru ErdoganDepartment of Dermatology and Venereology, Ufuk University Hospital, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate the changing trends in dermatology clinical practice at a tertiary center during the coronavirus disease 2019 (COVID-19) pandemic. This retrospective cohort study was conducted on patients who were admitted to Ufuk University Hospital with dermatologic complaints/diseases before and during the pandemic. The patients were divided into two groups: (a) the pre-pandemic period (March-May 2019) and (b) the Pandemic period (March-May 2020). Demographic features, clinical characteristics, dermatologic diseases/complaints, dermatologic procedures/interventions, hospitalization rate, and use of biologic agents were compared between the two groups. Total number of hospital admissions have decreased from 1165 to 717. Admission rates for acne, dermatophytosis, and benign neoplasm of the skin significantly lower during the pandemic period (P values were .02, .04, and .006, respectively). Contact dermatitis, acne accompanying dermatitis, cicatricial hair loss, lichen planus, and zona zoster infection rates were significantly higher (P values were .007, <.001, .009, .04, and .03, respectively). Rates of biopsy and electrocautery procedures were decreased significantly (P values were <.001 and .002, respectively). The hospitalization rate was similar between the groups (P = .51). However, the use of biologic agents significantly decreased during the pandemic period (P = .01). Updated clinical protocols should be established for the new normal period in accordance with these findings.

Indexed as

COVID-19AdultAgedBiological ProductsBiopsyDermatologistsDermatologyElectrocoagulationFemaleHumansMaleMiddle AgedPatient AdmissionPractice Patterns, Physicians'Retrospective StudiesSkin DiseasesBiological Productschanging clinical practiceCOVID-19dermatologypandemic

Identifiers

PMID32767466
PMCPMC7435568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.